Translumina Launches VIVO ISAR, the World’s First Dual-Drug Polymer-Free Coated Coronary Stent

New Delhi, India and Hechingen, Germany, April 19, 2022 /PRNewswire/ -- Translumina, a global developer and manufacturer of innovative cardiovascular medical devices in the field of interventional cardiology, announced the launch of its latest generation Dual Drug Coated Stent (DDCS) without polymer coating in multiple international markets, including Europe.VIVO ISAR。 

Translumina Therapeutics has always been synonymous with innovation in the field of interventional cardiology, and today's announcement further strengthens its global cardiovascular product portfolio.

Multiple studies have proven that polymers can trigger inflammation, which may lead to the formation of stent thrombosis. However, the current generation of DES must use polymers because they can control the drug release kinetics by serving as carriers for drug loading and release.

VIVO ISARIt is the first dual-drug polymer-free coronary stent technology, combining the stent with excellent safety without compromising drug release kinetics.VIVO ISARIt is the first technology to use Probucol, an antioxidant and lipid-lowering drug, as a carrier for releasing Sirolimus (an anti-restenosis drug), thereby creating a polymer-free DES platform without compromising safety and efficacy.

2020YearTranslumina becomes the world's only company to release its dual-drug polymer-free coating stent (DDCS)VIVO ISATCompany with ten-year follow-up data.《American HeartJournal of Cardiology》（JACC）Is one of the most important publications in the field of cardiology, and its Journal Citation Report has a high impact factor. The journalReleasedVIVO ISATTen-year safety and efficacy follow-up data.

“VIVO ISAR"The decade-long results represent a significant breakthrough in DES technology, as it has been proven that synthetic polymers can be removed from DES without compromising their effectiveness. The excellent safety demonstrated in the ten-year follow-up study is particularly noteworthy, as it provides a powerful new technology for treating complex coronary artery disease in high-risk patient subgroups. This DES technology shows great potential in significantly reducing the duration of dual antiplatelet therapy," said Adnan Kastrati, Director of the Cardiac Cath Lab at the German Heart Center Munich and principal investigator of the ISAR TEST5 trial. ISAR TEST5 willVIVO ISARCompared with the Drug-Eluting Coronary Stent System (Medtronic Inc, USA).

Patients with diabetes pose special challenges because the disease is associated with more diffuse lesions, making it difficult to achieve the best subsequent clinical outcomes after percutaneous coronary intervention.

2021Year, "American HeartJournal of the Zang AssociationReleasedVIVO ISARIn a diabetic patientCompelling Decade-Long Efficacy and Safety Data in Subgroups, highlighting its outstanding efficacy and safety. Compared with the drug-eluting coronary stent system, MI was reduced by 30%. Tranlumina has become the first company in the world to achieve the longest RCT follow-up through its flagship dual-drug eluting stent, bringing new hope to the subgroup of high-risk diabetic patients.

Translumina TherapeuticsVIVO ISARAlready inItaly and SpainIt has been launched in the market, with plans to launch in multiple markets across Europe, Latin America, and the Asia-Pacific region in the coming months.

"We are very pleased to offer high-quality stents to customers worldwide. Now, cardiologists around the world can choose to provide their patients with proven and safer drug-eluting stents. The performance of traditional DES is suboptimal, especially in high-risk diabetic subgroups."TransluminaDirectorGeneral Manager & Co-FounderGurmit Singh ChughRepresentation.

Everstone Capital invested in Translumina in 2019 to further strengthen its R&D pipeline, expand its manufacturing operations, and broaden its global reach, transforming Translumina into a leading multinational medical device company.

"Translumina is leading a global journey in creating the highest standards of clinical data, giving physicians more confidence and certainty when treating patients, and we are proud of that."Everstone CapitalDirectorGeneral ManagerArjun OberoiRepresentation。